Carl D. Regillo, MD, FACS
Show Description +
Carl D. Regillo, MD, FACS, provides a look at 3-year data from the phase 1 OPTIC extension trial of ixoberogene soroparvovec (Ixo-vec [formerly ADVM-022], Adverum Biotechnologies)—and a peek at the phase 2 LUNA trial.
Posted: 11/08/2023
Carl D. Regillo, MD, FACS
Carl D. Regillo, MD, FACS, provides a look at 3-year data from the phase 1 OPTIC extension trial of ixoberogene soroparvovec (Ixo-vec [formerly ADVM-022], Adverum Biotechnologies)—and a peek at the phase 2 LUNA trial.
Posted: 11/08/2023
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2023.
Please log in to leave a comment.